Caroxazone may increase the serotonergic activities of Olanzapine. Iproniazid may increase the serotonergic activities of Olanzapine. The risk or severity of adverse effects can be increased when Perazine is combined with Olanzapine. The therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Olanzapine. The risk or severity of adverse effects can be increased when Olanzapine is combined with Etorphine. The risk or severity of adverse effects can be increased when Etizolam is combined with Olanzapine. The serum concentration of Fluvastatin can be increased when it is combined with Olanzapine. The risk or severity of adverse effects can be increased when Olanzapine is combined with Propoxycaine. The metabolism of Olanzapine can be decreased when combined with Lorcaserin. The risk or severity of adverse effects can be increased when Olanzapine is combined with Methoxyflurane. The risk or severity of adverse effects can be increased when Olanzapine is combined with Agomelatine. The risk or severity of adverse effects can be increased when Olanzapine is combined with Lurasidone. The risk or severity of adverse effects can be increased when Olanzapine is combined with Oxethazaine. The risk or severity of adverse effects can be increased when Clonazepam is combined with Olanzapine. Olanzapine can cause a decrease in the absorption of Delavirdine resulting in a reduced serum concentration and potentially a decrease in efficacy. The risk or severity of adverse effects can be increased when Olanzapine is combined with Drotebanol. The therapeutic efficacy of Acarbose can be decreased when used in combination with Olanzapine. Olanzapine may increase the QTc-prolonging activities of Goserelin. Olanzapine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine. The risk or severity of adverse effects can be increased when Olanzapine is combined with Ropivacaine. The risk or severity of adverse effects can be increased when Olanzapine is combined with Etomidate. Minocycline may increase the central nervous system depressant (CNS depressant) activities of Olanzapine. The therapeutic efficacy of Insulin Human can be decreased when used in combination with Olanzapine. The risk or severity of adverse effects can be increased when Tramadol is combined with Olanzapine. The serum concentration of Olanzapine can be decreased when it is combined with Osimertinib. The risk or severity of adverse effects can be increased when Olanzapine is combined with Articaine. The risk or severity of adverse effects can be increased when Olanzapine is combined with Loxapine. The risk or severity of adverse effects can be increased when Olanzapine is combined with Trazodone. The risk or severity of adverse effects can be increased when Phenelzine is combined with Olanzapine. The therapeutic efficacy of Sulodexide can be decreased when used in combination with Olanzapine. The risk or severity of adverse effects can be increased when Ergonovine is combined with Olanzapine. The risk or severity of adverse effects can be increased when Olanzapine is combined with Meclizine. The risk or severity of adverse effects can be increased when Olanzapine is combined with Zotepine. The risk or severity of adverse effects can be increased when Olanzapine is combined with Clonidine. The risk or severity of adverse effects can be increased when Olanzapine is combined with Aripiprazole. The risk or severity of adverse effects can be increased when Olanzapine is combined with Alphacetylmethadol. The risk or severity of adverse effects can be increased when Olanzapine is combined with Sevoflurane. Olanzapine may increase the QTc-prolonging activities of Ibutilide. The risk or severity of adverse effects can be increased when Olanzapine is combined with Normethadone. The risk or severity of adverse effects can be increased when Olanzapine is combined with Ramelteon. The therapeutic efficacy of Acetohexamide can be decreased when used in combination with Olanzapine. Olanzapine may increase the QTc-prolonging activities of Toremifene. The therapeutic efficacy of Insulin Detemir can be decreased when used in combination with Olanzapine. The risk or severity of adverse effects can be increased when Olanzapine is combined with Ketamine. Pirlindole may increase the serotonergic activities of Olanzapine. The therapeutic efficacy of Insulin Pork can be decreased when used in combination with Olanzapine. The risk or severity of adverse effects can be increased when Olanzapine is combined with Methylecgonine. The serum concentration of Olanzapine can be increased when it is combined with Ranolazine. The therapeutic efficacy of Buformin can be decreased when used in combination with Olanzapine. Olanzapine may increase the QTc-prolonging activities of Erythromycin. The serum concentration of Ibrutinib can be increased when it is combined with Olanzapine. The serum concentration of Olanzapine can be increased when it is combined with Cobicistat. Olanzapine may increase the central nervous system depressant (CNS depressant) activities of Azelastine. Olanzapine may increase the QTc-prolonging activities of Amiodarone. The risk or severity of adverse effects can be increased when Tetrabenazine is combined with Olanzapine. The risk or severity of adverse effects can be increased when Frovatriptan is combined with Olanzapine. Olanzapine may increase the QTc-prolonging activities of Citalopram. The therapeutic efficacy of Phenformin can be decreased when used in combination with Olanzapine. The risk or severity of adverse effects can be increased when Olanzapine is combined with Mepivacaine. The risk or severity of adverse effects can be increased when Olanzapine is combined with Ethyl loflazepate. The risk or severity of adverse effects can be increased when Olanzapine is combined with Levobupivacaine. Desvenlafaxine may increase the serotonergic activities of Olanzapine. The risk or severity of adverse effects can be increased when Olanzapine is combined with Chlorzoxazone. Olanzapine may increase the QTc-prolonging activities of Dolasetron. Olanzapine may increase the QTc-prolonging activities of Vandetanib. The therapeutic efficacy of Repaglinide can be decreased when used in combination with Olanzapine. The therapeutic efficacy of Pramlintide can be decreased when used in combination with Olanzapine. The risk or severity of adverse effects can be increased when Olanzapine is combined with Chlorprothixene. The risk or severity of adverse effects can be increased when Linezolid is combined with Olanzapine. The risk or severity of adverse effects can be increased when Delorazepam is combined with Olanzapine. The metabolism of Olanzapine can be decreased when combined with Atomoxetine. Olanzapine may increase the QTc-prolonging activities of Promazine. Olanzapine may increase the QTc-prolonging activities of Dronedarone. The risk or severity of adverse effects can be increased when Nitrazepam is combined with Olanzapine. The risk or severity of adverse effects can be increased when Olanzapine is combined with Cetirizine. The risk or severity of adverse effects can be increased when Prazepam is combined with Olanzapine. Mebanazine may increase the serotonergic activities of Olanzapine. Olanzapine can cause a decrease in the absorption of Cefuroxime resulting in a reduced serum concentration and potentially a decrease in efficacy. The risk or severity of adverse effects can be increased when Olanzapine is combined with Ecopipam. The risk or severity of adverse effects can be increased when Olanzapine is combined with Fentanyl. The therapeutic efficacy of Allicin can be decreased when used in combination with Olanzapine. The risk or severity of adverse effects can be increased when Olanzapine is combined with Lofentanil. Olanzapine can cause an increase in the absorption of Risedronate resulting in an increased serum concentration and potentially a worsening of adverse effects. The metabolism of Olanzapine can be decreased when combined with Bupropion. Olanzapine may decrease the stimulatory activities of Amphetamine. Olanzapine may increase the QTc-prolonging activities of Lumefantrine. The risk or severity of adverse effects can be increased when Olanzapine is combined with Methsuximide. The risk or severity of adverse effects can be increased when Oxazepam is combined with Olanzapine. The risk or severity of adverse effects can be increased when Olanzapine is combined with Trans-2-Phenylcyclopropylamine. The therapeutic efficacy of Mesalazine can be decreased when used in combination with Olanzapine. The risk or severity of adverse effects can be increased when Olanzapine is combined with Methylphenobarbital. Olanzapine may increase the QTc-prolonging activities of Propafenone. The therapeutic efficacy of Linagliptin can be decreased when used in combination with Olanzapine. The risk or severity of adverse effects can be increased when Camazepam is combined with Olanzapine. The therapeutic efficacy of Tolazamide can be decreased when used in combination with Olanzapine. The risk or severity of adverse effects can be increased when Olanzapine is combined with Pentazocine. The metabolism of Tacrolimus can be decreased when combined with Olanzapine. The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Olanzapine. Olanzapine may decrease the stimulatory activities of Diethylpropion. Nefazodone may increase the serotonergic activities of Olanzapine. The risk or severity of adverse effects can be increased when Olanzapine is combined with Aceprometazine. The risk or severity of adverse effects can be increased when Olanzapine is combined with Levomethadyl Acetate. The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Olanzapine. The risk or severity of adverse effects can be increased when Flurazepam is combined with Olanzapine. Olanzapine can cause a decrease in the absorption of Pazopanib resulting in a reduced serum concentration and potentially a decrease in efficacy. The metabolism of Olanzapine can be decreased when combined with Desipramine. The metabolism of Olanzapine can be decreased when combined with Terbinafine. The serum concentration of Olanzapine can be decreased when it is combined with Cyproterone acetate. The risk or severity of adverse effects can be increased when Olanzapine is combined with Pizotifen. The risk or severity of adverse effects can be increased when Pentobarbital is combined with Olanzapine. The therapeutic efficacy of Amantadine can be decreased when used in combination with Olanzapine. The risk or severity of adverse effects can be increased when Olanzapine is combined with Tetrahydropalmatine. The serum concentration of Ubidecarenone can be increased when it is combined with Olanzapine. The risk or severity of adverse effects can be increased when Olanzapine is combined with Fospropofol. The risk or severity of adverse effects can be increased when Rizatriptan is combined with Olanzapine. Olanzapine may increase the arrhythmogenic activities of Mequitazine. Olanzapine may increase the QTc-prolonging activities of Disopyramide. The risk or severity of adverse effects can be increased when Tedizolid Phosphate is combined with Olanzapine. The serum concentration of Itraconazole can be decreased when it is combined with Olanzapine. The risk or severity of adverse effects can be increased when Olanzapine is combined with Brotizolam. The risk or severity of adverse effects can be increased when Olanzapine is combined with Fluticasone propionate. The risk or severity of adverse effects can be increased when Olanzapine is combined with Enflurane. Nabilone may increase the central nervous system depressant (CNS depressant) activities of Olanzapine. The metabolism of Olanzapine can be decreased when combined with Imipramine. The risk or severity of adverse effects can be increased when Olanzapine is combined with Pethidine. The risk or severity of adverse effects can be increased when Olanzapine is combined with Melperone. The therapeutic efficacy of Pioglitazone can be decreased when used in combination with Olanzapine. The risk or severity of adverse effects can be increased when Olanzapine is combined with Desloratadine. The risk or severity of adverse effects can be increased when Olanzapine is combined with Risperidone. The risk or severity of adverse effects can be increased when Olanzapine is combined with Trichloroethylene.